Bioxcel Therapeutics is a biopharmaceutical company focused on innovative drug development to address unmet medical needs in the fields of neurology and psychiatry
Utilizing its proprietary artificial intelligence platform, the company aims to identify and advance novel therapeutics that can improve patient outcomes in challenging conditions such as agitation in Alzheimer's patients and cancer-related symptoms. Bioxcel's approach integrates data-driven decision-making and clinical research to bring forth potential treatments that enhance the quality of life for patients dealing with complex health issues.
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session.
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
USA News Group Commentary Issued on behalf of Avant Technologies Inc. Vancouver, BC – December 17, 2024 – USA News Group News Commentary – Artificial intelligence (AI) is on the brink of becoming a critical resource in healthcare, moving beyond its status as a novel concept. With over 800 FDA-cleared AI applications already in […]
BioXcel Therapeutics shares topline results from an Igalmi (dexmedetomidine) sublingual film study. The 180 mcg dose demonstrated favorable safety and efficacy in reducing agitation symptoms.
From no AI category losses in February, to 3 drops in March - now all 7 fell this week, clearly indicating that that the surge in AI stock prices that began back on October 31st is, indeed, over.
All but one of the 7 artificial intelligence stock categories that I analyze weekly increased in value this week. But two categories are still down MTD, suggesting that the surge in the artificial intelligence technology sector is slowing.
The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway.
